GI
BMRN icon

GAMMA Investing’s BioMarin Pharmaceuticals BMRN Stock Holding History

GAMMA Investing’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$219K Buy
3,642
+1,220
+50% +$76.8K 0.01% 1258
2026
Q2 		$139K Buy
2,422
+734
+43% +$40.2K 0.01% 1556
2026
Q1 		$95.4K Buy
1,688
+1,151
+214% +$67.1K ﹤0.01% 1710
2025
Q4 		$31.9K Sell
537
-679
-56% -$37K ﹤0.01% 2346
2025
Q3 		$65.9K Sell
1,216
-450
-27% -$25.7K ﹤0.01% 1810
2025
Q2 		$91.6K Sell
1,666
-1,463
-47% -$86.2K 0.01% 1515
2025
Q1 		$221K Buy
3,129
+1,897
+154% +$128K 0.02% 714
2024
Q4 		$81K Buy
1,232
+450
+58% +$30.1K 0.01% 1275
2024
Q3 		$55K Buy
782
+281
+56% +$23.5K 0.01% 1423
2024
Q2 		$41.2K Buy
501
+111
+28% +$9.24K 0.01% 1328
2024
Q1 		$34.1K Buy
390
+115
+42% +$10.3K 0.01% 1284
2023
Q4 		$24.2K Buy
+275
New +$24.3K 0.01% 1366

Other funds holding BMRN

FFBTD
First Financial Bank - Trust Division Hamilton, Ohio $1.39B AUM 15.59% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MGI
Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

GAMMA Investing's BMRN Position: Q3 2026 in Review

GAMMA Investing increased its BioMarin Pharmaceuticals (BMRN) stake by 50% in Q3 2026, buying an estimated $76.8K and bringing the position to 3,642 shares worth $219K. The position accounts for 0.01% of the portfolio, ranked #1258.

GAMMA Investing first reported a position in BMRN in Q4 2023 and has held it in 12 quarters since. The position peaked at $221K in Q1 2025. 17 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • GAMMA Investing held 3,642 shares of BioMarin Pharmaceuticals worth $219K as of Q3 2026.
  • GAMMA Investing bought 1,220 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $76.8K.
  • BioMarin Pharmaceuticals made up 0.01% of GAMMA Investing's portfolio in Q3 2026, its #1258 holding.
  • GAMMA Investing first reported a position in BioMarin Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's BioMarin Pharmaceuticals position peaked at $221K in Q1 2025.
  • 17 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.